<DOC>
	<DOCNO>NCT00312078</DOCNO>
	<brief_summary>The purpose study determine whether special yogurt improve performance certain test intelligence decrease liver inflammation patient cirrhosis .</brief_summary>
	<brief_title>Effect Yogurt Minimal Hepatic Encephalopathy</brief_title>
	<detailed_description>Introduction : Cirrhosis one leading cause death United States . Minimal hepatic encephalopathy ( MHE ) significant complication cirrhosis , often treat perceived subclinical nature condition adverse effect expense available medication lactulose rifaximin . There evidence small intestinal bacterial overgrowth contribute development MHE cirrhosis murine human study . Probiotics live bacteria modify indigenous intestinal bacterial flora recently use treatment hepatic encephalopathy patient cirrhosis . Our aim evaluate effect probiotic supplementation via yogurt liver function inflammatory marker bacterial translocation psychometric test performance cirrhotic patient MHE prospective pilot trial . Methods : 30 patient MHE 2:1 i.e . 20 randomized supplementation yogurt take 6 ounce twice day 60 day 10 patient follow without yogurt supplementation . All patient undergo liver function test , basic metabolic panel , INR , venous ammonia , IL-6 TNF-alpha baseline , 30 day 60 day . All patient also undergo psychometric test number connection test A , digit symbol test , block design inhibitory control test baseline 60 day . Regular question adherence yogurt . Collection yogurt top proof yogurt consumption review intake diary do 30 60 day patient randomized yogurt supplementation . Importance : There one human study modification gut flora therapeutic tool improvement MHE cirrhosis , however study include alcoholic liver disease comprise Chinese patient , therefore etiology liver disease study different predominant United States . Since MHE adversely affect quality life overall prognosis , simple , target therapy need treat . We believe pilot study help delineate human gut flora definite target therapy cirrhosis MHE pave way future large-scale study subject .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<criteria>Cirrhosis diagnose clinical ground ( within 3 month enrollment ) MHE diagnose abnormality psychometric battery ( NCTA , BDT , DST ICT ) Exclusion criterion : Current recent ( &lt; 6 month ) use alcohol Coexisting cause liver dysfunction Use antibiotic within last 6 week Infection gastrointestinal hemorrhage within last 6 week Hepatocellular carcinoma Psychoactive drug use , include interferon concurrently</criteria>
	<gender>All</gender>
	<minimum_age>24 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Minimal Hepatic Encephalopathy</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>